BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/21/2020 6:56:33 AM | Browse: 764 | Download: 920
Publication Name World Journal of Gastroenterology
Manuscript ID 52516
Country/Territory Japan
Received
2019-12-30 18:51
Peer-Review Started
2019-12-30 18:52
To Make the First Decision
Return for Revision
2020-02-29 22:27
Revised
2020-03-05 15:34
Second Decision
2020-04-03 12:48
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2020-04-04 02:53
Articles in Press
2020-04-04 02:53
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2020-04-20 01:48
Publish the Manuscript Online
2020-04-21 06:56
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Infectious Diseases
Manuscript Type Minireviews
Article Title Update on quinolone-containing rescue therapies for Helicobacter pylori infection
Manuscript Source Invited Manuscript
All Author List Hideki Mori and Hidekazu Suzuki
ORCID
Author(s) ORCID Number
Hideki Mori http://orcid.org/0000-0001-8830-4671
Hidekazu Suzuki http://orcid.org/0000-0002-8994-6163
Funding Agency and Grant Number
Corresponding Author Hideki Mori, MD, PhD, Doctor, Postdoctoral Fellow, Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders, University of Leuven, Herestraat 49 Box 701, Leuven 3000, Belgium. hideki.mori@kuleuven.be
Key Words Helicobacter pylori; Levofloxacin; Sitafloxacin; Moxifloxacin; gyrA; Vonoprazan
Core Tip The efficacies of 7-d levofloxacin or moxifloxacin, -containing regimens are becoming less effective in recent years due to the increasing antibiotic resistance, which necessitates 10-d or 14-d regimens or bismuth containing regimen are needed to achieve sufficient eradication rates. gyrA mutation is the most sensitive marker for predicting successful eradication in using quinolone-containing therapies. Thus, analysis of gyrA mutation before treatments is recommended. Seven-day sitafloxacin-amoxicillin-vonoprazan triple therapy is the best choice for third-line treatment at present.
Publish Date 2020-04-21 06:56
Citation Mori H, Suzuki H. Update on quinolone-containing rescue therapies for Helicobacter pylori infection. World J Gastroenterol 2020; 26(15): 1733-1744
URL https://www.wjgnet.com/1007-9327/full/v26/i15/1733.htm
DOI https://dx.doi.org/10.3748/wjg.v26.i15.1733
Full Article (PDF) WJG-26-1733.pdf
Full Article (Word) WJG-26-1733.docx
Manuscript File 52516-Review.docx
Answering Reviewers 52516-Answering reviewers.pdf
Audio Core Tip 52516-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 52516-Conflict-of-interest statement.pdf
Copyright License Agreement 52516-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate 52516-Language certificate.pdf
Peer-review Report 52516-Peer-review(s).pdf
Scientific Misconduct Check 52516-Scientific misconduct check.pdf
Scientific Editor Work List 52516-Scientific editor work list.pdf